Back to results
US 7,247,300 B1Granted
Therapeutic use of soluble CD39L3
AssigneeAPT Therapeutics, Inc.
InventorsRidong Chen, Soon S. Jeong, Timothy A. Mitsky
Life of this patent
Estimating the term…
Abstract
The present invention provides soluble forms of CD39L3 polypeptides and compositions, and methods useful inhibiting platelet activation and recruitment for the treatment and prevention of thrombotic disorders in mammals administered with soluble forms of CD39L3 polypeptides.
Claims15
An isolated polypeptide consisting of an amino acid sequence at least 95% identical to positions 44-484 of SEQ ID NO:20 and which has apyrase activity.
Dependencies are inferred from the claim text.